Recent data regarding the overexpression of PSMA in advanced prostate cancer has led to a therapeutic opportunity of utilizing PSMA as radioligand targeted therapy, possibly as an additional line of treatment in these patients. This evidence concerns the gene FOLH1 and Familial prostate cancer.